Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma

Table 1 patient characteristics

Characteristic	Case subjects (n = 29)
Sex
Male (n)	21
Female (n)	8
Age at diagnosis, yr (mean ± SEM)	69.1 ± 2.1
BMI, kg/m² (mean ± SEM)	26.6 ± 1.0
BCLC stage (n)
BCLB-B	1
BCLB-C	28
HCC characteristics (n)
Bilobar	18/28
Multifocal	15/26
Vascular invasion	8/29
UP-TO-7-Criteria	16/29
Metastasis (n)
No metastases	16
1 meta location	8
2 meta locations	3
4 meta locations	2
AFP at baseline, ng/mL (mean ± SEM)	4375.6 ± 2566.6
Cirrhosis (n)
No Cirrhosis	10
CP A	10
CP B	8
Unknown	1
Origin cirrhosis (n)
HBV	4
HCV	2
Ethyl	7
NAFLD	3
Other	2
Missing	1
WHO performance status (n)
0	5
1	21
2	3
Previous treatment (n) (Resection, radiofrequency ablation, transarterial radioembolization, transarterial chemoembolization, selective internal radiation therapy, sorafenib, capecitabine, GEMOX, doxorubicine, FOLFOX, regorafenib, cabozantinib)
Yes	27
No	2

WHO: World Health Organization; CP: Child-Pugh; BMI: Body mass index; BCLC: Barcelona clinic liver cancer; HCC: Hepatocellular cancer; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NAFLD: Nonalcoholic fatty liver disease.